Obesity and type 2 diabetes remain major global health burdens, with WHO estimating that roughly 890 million people were living with obesity in 2022 and 2.5 billion adults were overweight. GLP-1 therapies have already changed treatment expectations, but the larger story now is how quickly the field is moving beyond first-generation agents toward longer-acting formats, oral options, multi-target agonists, and new metabolic pathways.
This broader innovation starts with biology itself. GLP-1 remains foundational because it enhances insulin secretion when glucose is elevated, helping explain both its metabolic utility and relatively low hypoglycemia risk. At the same time, glucose-dependent insulinotropic polypeptide (GIP) has re-emerged as a viable obesity target, while glucagon is increasingly being used in combination strategies for obesity and metabolic dysfunction-associated steatotic liver disease (MASLD), expanding the design space beyond single-pathway optimization.
Longer-Acting Therapies Changed Expectations
The first major wave of innovation in this category was not a new target but a pharmacokinetic evolution. The primary goal was to extend the half-life and improve dosing convenience of early GLP-1s, thereby creating long-term adherence. Those early drugs (e.g., exenatide) helped validate the mechanism, but their shorter duration limited flexibility, with exenatide’s half-life reported at about 2.4 hours. By comparison, liraglutide improved on that profile through amino acid substitutions and fatty acid side-chain modifications, extending its half-life to roughly 13 hours, while later-generation agents pushed exposure beyond 120 hours and made once-weekly dosing a practical clinical reality.
This progress was especially notable because it achieved outcomes through multiple technical routes rather than single-platform solution. Across the category, developers tried a host of strategies to reduce clearance and extend exposure, including:
- Microsphere sustained-release systems in exenatide
- IgG4-Fc conjugation in dulaglutide
- Albumin-binding fatty acid side chains in semaglutide
- PEG-based modification in loxenatide
- Microneedles to enable sustained delivery through the skin
Once longer-duration therapy became achievable, the next logical question was whether these drugs could also become easier to administer and digest.
Oral Delivery Is the Next Competitive Frontier
If longer-acting injectables improve convenience, oral delivery could dramatically reshape the category’s competitive dynamics. Oral semaglutide offered an important proof point that at least some peptide-delivery barriers can be overcome, in this case through the absorption enhancer SNAC, which increases semaglutide bioavailability 100-fold. Mechanistically, SNAC promotes semaglutide monomerization, alters the gastric epithelial membrane environment to improve penetration, and increases local pH around the drug to reduce pepsin-mediated degradation and facilitate absorption across the gastric mucosa.
But the oral opportunity is no longer limited to reformulating peptides. Emerging small-molecule approaches such as orforglipron suggest that the field is now testing whether non-peptide oral GLP-1 receptor agonists can combine convenience with differentiated signaling and, potentially, a different development and manufacturing profile. Orforglipron is a once-daily oral partial agonist with greater activity on cAMP signaling than on β-arrestin recruitment, a bias that may reduce receptor desensitization relative to full GLP-1 agonists. At the same time, oral delivery introduces its own strategic questions, including how to manage off-target toxicity in small molecules, how to further improve peptide bioavailability, and how to differentiate new products in a market that is becoming increasingly crowded. In addition to formulation innovation, many developers are also trying to improve outcomes by redesigning the pharmacology itself.
Multi-Target Drugs Are Redefining the Category
Perhaps the clearest sign that the field has moved beyond first-generation GLP-1 thinking is the rise of dual- and triple-agonist programs designed to combine complementary metabolic effects in a single molecule. Tirzepatide marked an important milestone as the first FDA-approved GIP/GLP-1 dual agonist in 2022, and the field broadened with the development of mazdutide, a GLP-1R/GCGR dual-target therapy approved by NMPA in 2025, and retatrutide (still in clinical trials), which extends the concept further through triple agonism at GLP-1R, GIPR, and GCGR[Pe1] . Drug developers are trying to coordinate several pathways simultaneously to improve weight loss, metabolic control, and possibly overall therapeutic balance.
These programs reflect deliberate attempts to engineer synergy while preserving drug-like properties. The underlying molecular design is increasingly sophisticated, with acylated fatty acid fragments used to promote albumin binding and extend half-life, alongside targeted amino acid substitutions that improve DPP-IV stability and tune receptor activity across GLP-1R, GIPR, and GCGR. In retatrutide, for example, Aib2 helps improve stability against DPP-IV, Aib20 may optimize GIP activity and pharmacokinetic behavior, and αMeL13 is used to optimize glucagon and GIP activity. More broadly, many clinical-stage candidates combine GLP-1R agonism with GIPR, GCGR, FGF21R, or GLP-2R, illustrating how quickly multi-target design has become a central organizing principle in the field. And yet even that may not define the outer boundary of metabolic drug development, as companies increasingly look beyond incretin and glucagon receptors altogether.
New Targets Point Beyond Incretins
The next phase of metabolic drug development may be defined not only by better incretin combinations but also by mechanisms that address adjacent goals such as body composition, satiety, and weight-loss durability. A few new-target examples have seen mixed success:
- ActRII blockade: Appears to influence both fat metabolism and skeletal muscle preservation, making it attractive in a field where preserving lean mass matters as much as reducing scale weight.
- Bimagrumab: reduces HbA1c, increases lean mass, reduces fat mass, and leads to overall weight loss, reinforcing the idea that future obesity therapies may need to be judged by body composition, not just total body weight.
- Amylin: Uses a satiety-driven mechanism to slow gastric emptying and reduce food intake via a well-defined neurohormonal pathway.
- Pramlintide: Showed early promise, but its meal-time injection burden and formulation limitations made it impractical as a broad stand-alone solution.
Newer combinations such as CagriSema are also important, suggesting that amylin-based strategies may still have room to evolve when paired with more durable dosing and stronger metabolic control. These newer targets broaden the opportunities and raise the bar for differentiation and development planning.
A Final Word: What Will Differentiate the Next Wave of GLP-1s
The opportunity remains enormous, but future drug developers and sponsors will be judged on more than efficacy. GI tolerability, weight regain after discontinuation, thyroid-risk scrutiny, oral bioavailability, off-target toxicity, and clear differentiation will matter just as much as headline-grabbing weight-loss data. The winners are likely to be the companies that approach metabolic drug development as a multidimensional optimization problem spanning biology, delivery, safety, and patient experience.
